Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Metsera plans to initiate a Phase 2b trial of MET-097 in Q4 2024, with data anticipated in the first half of 2025.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In preclinical studies ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may preserve lean muscle mass compared to currently ...

In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.

Biomed Industries Unveils novel Quadruple Receptor Agonist for weight loss with Minimal Adverse Effects at the International Obesity conference in Las Vegas Dr. Lloyd L. Tran Biomed Industries, Inc.

Global GLP-1 Analogues Market is valued at approximately USD 35.59 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 33% over the forecast period 2024-2032. Read the ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Aberrant G-protein coupled ...

Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...

Weight loss drugs have gained attention as a tool to help combat obesity, but understanding how they work, who they’re for, ...

Representational Photo The exploration of novel peptides for their potential impact on metabolic pathways has been a ...

For significant weight loss, Zepbound may be the better option. If you have Type 2 diabetes and are looking for a dual ...